StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research report report published on Wednesday morning. The brokerage issued a sell rating on the stock. Navidea Biopharmaceuticals Price Performance NAVB opened at $0.08 on Wednesday. The company’s 50 day simple moving average is $0.09 and its two-hundred day simple moving […]
StockNews.com initiated coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a report issued on Tuesday morning. The brokerage issued a sell rating on the stock. Navidea Biopharmaceuticals Price Performance Shares of NYSE:NAVB opened at $0.07 on Tuesday. Navidea Biopharmaceuticals has a twelve month low of $0.07 and a twelve month high of […]
StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research report released on Tuesday morning. The brokerage issued a sell rating on the stock. Navidea Biopharmaceuticals Stock Performance NYSE:NAVB opened at $0.07 on Tuesday. Navidea Biopharmaceuticals has a one year low of $0.07 and a one year high of $0.62. […]
A number of research firms have changed their ratings and price targets for Navidea Biopharmaceuticals (NYSE: NAVB): 7/8/2023 – Navidea Biopharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock. 6/30/2023 – Navidea Biopharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock. […]
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB – Free Report) was the recipient of a large drop in short interest during the month of June. As of June 15th, there was short interest totalling 570,200 shares, a drop of 35.3% from the May 31st total of 881,100 shares. Currently, 4.5% of the company’s shares are short sold. Based […]